ATE296313T1 - Hla-a2.1 bindende peptide und deren verwendung - Google Patents

Hla-a2.1 bindende peptide und deren verwendung

Info

Publication number
ATE296313T1
ATE296313T1 AT97918494T AT97918494T ATE296313T1 AT E296313 T1 ATE296313 T1 AT E296313T1 AT 97918494 T AT97918494 T AT 97918494T AT 97918494 T AT97918494 T AT 97918494T AT E296313 T1 ATE296313 T1 AT E296313T1
Authority
AT
Austria
Prior art keywords
hla
binding peptides
peptides
allele
immunogenic
Prior art date
Application number
AT97918494T
Other languages
English (en)
Inventor
Howard M Grey
Alessandro Sette
John Sidney
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Application granted granted Critical
Publication of ATE296313T1 publication Critical patent/ATE296313T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97918494T 1996-03-21 1997-03-21 Hla-a2.1 bindende peptide und deren verwendung ATE296313T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1398096P 1996-03-21 1996-03-21
US82238297A 1997-03-20 1997-03-20
PCT/US1997/005348 WO1997034621A1 (en) 1996-03-21 1997-03-21 Hla-a2.1 binding peptides and their uses

Publications (1)

Publication Number Publication Date
ATE296313T1 true ATE296313T1 (de) 2005-06-15

Family

ID=26685499

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97918494T ATE296313T1 (de) 1996-03-21 1997-03-21 Hla-a2.1 bindende peptide und deren verwendung

Country Status (9)

Country Link
EP (1) EP0907370B1 (de)
JP (1) JP4210735B2 (de)
CN (1) CN1218406A (de)
AT (1) ATE296313T1 (de)
AU (1) AU2658897A (de)
BR (1) BR9708220A (de)
CA (1) CA2248667C (de)
DE (1) DE69733352T2 (de)
WO (1) WO1997034621A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
EP1064022A4 (de) * 1998-03-13 2004-09-29 Epimmune Inc Hla-bindeproteine und deren verwendung
AU1075001A (en) * 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
ATE298346T1 (de) 1999-12-06 2005-07-15 Chu Sainte Justine Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CA2400215A1 (en) * 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
EP1343819A4 (de) * 2000-09-01 2005-03-23 Epimmune Inc Hla-a2.1- bindungspeptide und ihre verwendung
US6974574B2 (en) 2001-08-16 2005-12-13 The General Hospital Corporation Methods of inducing an HIV specific response using a Vpr-specific epitope
WO2004035752A2 (en) 2002-10-15 2004-04-29 Protein Design Labs, Inc. ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1673395A1 (de) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Veränderungen der serum-halbwertszeiten von fc-fusionsprotein durch mutagenese der position 250, 314 und/oder 428 der schweren kette der konstanten region von ig
DE102005020911A1 (de) * 2005-05-04 2006-11-16 Carl Zeiss Meditec Ag Verfahren zur Messung der Änderung des Polarisationszustands von polarisierter optischer Strahlung durch eine optisch aktive Schicht eines Körpers und/oder einer Konzentration eines optisch aktiven Stoffs in der Schicht und Vorrichtung zur Durchführung des Verfahrens
WO2007008488A2 (en) 2005-07-06 2007-01-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Stable quantitation and detection of immune response levels with non-zero background peptides
BRPI0813626A2 (pt) * 2007-07-27 2014-12-23 Immatics Biotechnologies Gmbh Epitopos imunogênicos para a imunoterapia
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CN103282375B (zh) 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计
AU2012204955B2 (en) 2011-01-06 2016-10-06 Bionor Immuno As Monomeric and multimeric immunogenic peptides
MX2014014683A (es) 2012-06-06 2015-02-24 Bionor Immuno As Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
EP2745845A1 (de) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux Verfahren zur Vorbeugung oder Behandlung einer HIV-Infektion
CN105200010B (zh) * 2015-10-15 2019-02-12 首都医科大学附属北京佑安医院 艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000912A1 (en) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production and use of hybrid protease inhibitors
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
AU2361595A (en) * 1994-04-22 1995-11-16 Sloan-Kettering Institute For Cancer Research Induction of cytotoxic t lymphocytes (ctl) using antigenic peptides and a suitable adjuvant
EP0793501A4 (de) * 1994-12-14 2000-05-03 Scripps Research Inst 'in vivo'aktivierung von tumorspezifischen-zytotoxischen t-zellen

Also Published As

Publication number Publication date
JP2002515869A (ja) 2002-05-28
EP0907370A1 (de) 1999-04-14
BR9708220A (pt) 2000-01-04
DE69733352D1 (de) 2005-06-30
DE69733352T2 (de) 2006-04-27
AU2658897A (en) 1997-10-10
CA2248667C (en) 2012-06-05
JP4210735B2 (ja) 2009-01-21
EP0907370B1 (de) 2005-05-25
CN1218406A (zh) 1999-06-02
EP0907370A4 (de) 1999-10-20
WO1997034621A1 (en) 1997-09-25
CA2248667A1 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
DE69733352D1 (de) Hla-a2.1 bindende peptide und deren verwendung
BR9406652A (pt) Composição
EP1189624A4 (de) Hla-bindende peptide und deren verwendung
AU2001298049A8 (en) Hla class i and ii binding peptides and their uses
SG52492A1 (en) Hla binding peptides and their uses
DK0941478T4 (da) Assaymetode for peptidspecifikke T-celler
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
EP0997477A3 (de) MHC-Komplexe und ihre Verwendung
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
IL102687A0 (en) Method for enhancing immunogenicity
DE69333382D1 (de) Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide
ATE429247T1 (de) Hla-bindende peptide und ihre verwendungen
PT1272633E (pt) Composições e métodos para imunoterapia baseada em células dendríticas
AU2000273396A1 (en) Hla binding peptides and their uses
WO1999009167A8 (en) Porcine mhc class i genes and uses thereof
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties